The microbiome therapeutics landscape shows remarkable growth with over 140 companies actively developing 180+ pipeline drugs, spanning various disease areas and therapeutic approaches.
VE303, a defined bacterial consortium, significantly reduced the risk of recurrent Clostridioides difficile infection (rCDI) in a Phase 2 trial compared to placebo.
BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.